Peter Zdziarski: A Brighter Future for Glanzmann Thrombasthenia Through Gene Therapy
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
“It’s Rare Disease Day, and tomorrow is the official Glanzmann Thrombasthenia Awareness Day.
I was born with GT, and knowing that I may see gene therapy in my lifetime is incredible.
Through every challenge and every win, I wouldn’t change my journey.
The people I’ve met, the knowledge I’ve gained, and the places this path has taken me have shaped who I am, and I’m truly grateful.
Please consider donating to the Medical College of Wisconsin.
Every contribution moves us closer to a future where people with GT have more than just a couple of treatment options.
But a true solution.
A future with fewer antibodies from platelet transfusions, fewer dangerous bleeds, less bruising, and fewer long hospital stays.
The future is bright.
Donate toward gene therapy.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 19:43Abdul Mannan: Why Is HbS or HbD Approximately 40% in Heterozygotes Rather Than 50%?
-
Jul 21, 2026, 19:42Haemophilia Maintains a 2025 Impact Factor of 3.0 – WFH
-
Jul 21, 2026, 19:41Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
-
Jul 21, 2026, 19:40Filmon Tesfay: Our New Case Report on Cerebral Venous Thrombosis Is Now Published
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation